A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Running, not enrolling · Phase 1
Conditions studied: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
In brief
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Key facts
- Study ID
- NCT06360354
- Run by
- Amgen
- People needed
- 120
- Starts
- 2024-05-29
- Expected to finish
- 2026-11-30
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope National Medical Center — Duarte, California, United States
- City of Hope Orange County Lennar Foundation Cancer Center — Duarte, California, United States
- University of California San Diego Moores Cancer Center — La Jolla, California, United States
- Translational Research in Oncology US Inc, Trio Central Pharmacy — Los Angeles, California, United States
- University of California Los Angeles — Santa Monica, California, United States
- Rocky Mountain Cancer Centers — Aurora, Colorado, United States
- Hartford Hospital — Hartford, Connecticut, United States
- Yale University — New Haven, Connecticut, United States
- Norwalk Hospital — Norwalk, Connecticut, United States
- University of Chicago — Chicago, Illinois, United States
- Indiana University — Indianapolis, Indiana, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Washington University — St Louis, Missouri, United States
- University of Nebraska — Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Duke University — Durham, North Carolina, United States
- Cleveland Clinic Foundation — Cleveland, Ohio, United States
- United States Oncology Regulatory Affairs Corporate Office — Nashville, Tennessee, United States
- Oncology Consultants Cancer Center — Houston, Texas, United States
- US Oncology Research Investigational Products Center — Irving, Texas, United States
- University of Virginia Cancer Center — Charlottesville, Virginia, United States
- Comprehensive Blood and Cancer Center — Bakersfield, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.